Summary | |
---|---|
Symbol | MSLN |
Name | mesothelin |
Aliases | MPF; CAK1 antigen; megakaryocyte potentiating factor; pre-pro-megakaryocyte-potentiating factor; soluble MPF ...... |
Chromosomal Location | 16p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell membrane; Lipid-anchor, GPI-anchor. Golgi apparatus.; SUBCELLULAR LOCATION: Megakaryocyte-potentiating factor: Secreted.; SUBCELLULAR LOCATION: Isoform 3: Secreted. |
Domain |
PF06060 Pre-pro-megakaryocyte potentiating factor precursor (Mesothelin) |
Function |
Membrane-anchored forms may play a role in cellular adhesion.; FUNCTION: Megakaryocyte-potentiating factor (MPF) potentiates megakaryocyte colony formation in vitro. |
Biological Process |
GO:0007160 cell-matrix adhesion GO:0031016 pancreas development GO:0031589 cell-substrate adhesion |
Molecular Function | - |
Cellular Component |
GO:0031225 anchored component of membrane |
KEGG | - |
Reactome |
R-HSA-392499: Metabolism of proteins R-HSA-163125: Post-translational modification R-HSA-597592: Post-translational protein modification |
Summary | |
---|---|
Symbol | MSLN |
Name | mesothelin |
Aliases | MPF; CAK1 antigen; megakaryocyte potentiating factor; pre-pro-megakaryocyte-potentiating factor; soluble MPF ...... |
Chromosomal Location | 16p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between MSLN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between MSLN and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | MSLN |
Name | mesothelin |
Aliases | MPF; CAK1 antigen; megakaryocyte potentiating factor; pre-pro-megakaryocyte-potentiating factor; soluble MPF ...... |
Chromosomal Location | 16p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of MSLN in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | MSLN |
Name | mesothelin |
Aliases | MPF; CAK1 antigen; megakaryocyte potentiating factor; pre-pro-megakaryocyte-potentiating factor; soluble MPF ...... |
Chromosomal Location | 16p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of MSLN in various data sets.
|
Points in the above scatter plot represent the mutation difference of MSLN in various data sets.
|
Summary | |
---|---|
Symbol | MSLN |
Name | mesothelin |
Aliases | MPF; CAK1 antigen; megakaryocyte potentiating factor; pre-pro-megakaryocyte-potentiating factor; soluble MPF ...... |
Chromosomal Location | 16p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MSLN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | MSLN |
Name | mesothelin |
Aliases | MPF; CAK1 antigen; megakaryocyte potentiating factor; pre-pro-megakaryocyte-potentiating factor; soluble MPF ...... |
Chromosomal Location | 16p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MSLN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MSLN. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | MSLN |
Name | mesothelin |
Aliases | MPF; CAK1 antigen; megakaryocyte potentiating factor; pre-pro-megakaryocyte-potentiating factor; soluble MPF ...... |
Chromosomal Location | 16p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MSLN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | MSLN |
Name | mesothelin |
Aliases | MPF; CAK1 antigen; megakaryocyte potentiating factor; pre-pro-megakaryocyte-potentiating factor; soluble MPF ...... |
Chromosomal Location | 16p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of MSLN expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | MSLN |
Name | mesothelin |
Aliases | MPF; CAK1 antigen; megakaryocyte potentiating factor; pre-pro-megakaryocyte-potentiating factor; soluble MPF ...... |
Chromosomal Location | 16p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between MSLN and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | MSLN |
Name | mesothelin |
Aliases | MPF; CAK1 antigen; megakaryocyte potentiating factor; pre-pro-megakaryocyte-potentiating factor; soluble MPF ...... |
Chromosomal Location | 16p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting MSLN collected from DrugBank database. |
Details on drugs targeting MSLN.
|